Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study)

References

• Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003;423:356–61.
   PubMed Web of Science ®Google Scholar
• Weaver AL. The impact of new biologicals in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2004;43[Suppl 31:17–23.
   Google Scholar
• Keystone EC. Clinical implications of understanding radio-graphic findings in relation to clinical outcomes in rheumatoid arthritis. J Rheumatol Suppl. 2009;82:11–6.
   PubMedGoogle Scholar
• Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397–440.
   PubMed Web of Science ®Google Scholar
• Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthri-tis. Lancet. 1994;344:1105–10.
   PubMed Web of Science ®Google Scholar
• Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997;337:141–7.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Han C, Bala M, et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheu-matoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum. 2005;52:1020–30.
   PubMed Web of Science ®Google Scholar
• Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate com-pared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363:675–81.
   PubMed Web of Science ®Google Scholar
• Emery P, Breedveld FC, Hall S, et al. Comparison of metho-trexate monotherapy with a combination of methotrexate and e-tanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008;372:375–82.
   PubMed Web of Science ®Google Scholar
• Kalliolias GD, Liossis SN. The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis. Expert Opin Investig Drugs. 2008;17:349–59.
   PubMed Web of Science ®Google Scholar
• Abramson SB, Amin A. Blocking the effects of IL-1 in rheu-matoid arthritis protects bone and cartilage. Rheumatology (Oxford). 2002;41:972–80.
   PubMed Web of Science ®Google Scholar
• Kishimoto T. Interleukin-6: from basic science to medicine-40 years in immunology. Annu Rev Immunol. 2005;23:1–21.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Yoshizaki K, Maeda K, et al. Toxicity, pharma-colcinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheu-matoid arthritis. Phase I/II clinical study. J Rheumatol. 2003;30: 1426–35.
   Google Scholar
• Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2004;50:1761–9.
   PubMed Web of Science ®Google Scholar
• Maini RN, Taylor PC, Szechinski J, et al. Double-blind ran-domized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54:2817–29.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007;66:1162–7.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of inter-leukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371: 987–97.
   Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classifica-tion of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.
   PubMed Web of Science ®Google Scholar
• Koike R, Harigai M, Atsumi T, et al. Japan College of Rheuma-tology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod Rheumatol. 2009;19:351–7.
   PubMed Web of Science ®Google Scholar
• Prevoo ML, van 't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44–8.
   Google Scholar
• Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23:137–45.
   PubMed Web of Science ®Google Scholar
• Matsuda Y, Singh G, Yamanaka H, et al. Validation of a Japanese version of the Stanford Health Assessment Questionnaire in 3,763 patients with rheumatoid arthritis. Arthritis Rheum. 2003;49:784–8.
   PubMed Web of Science ®Google Scholar
• van Gestel AM, Prevoo ML, van 't Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 1996;39:34–40.
   Google Scholar
• Yamanaka H, Inoue E, Tanaka E, et al. Influence of methotrexate dose on its efficacy and safety in rheumatoid arthritis patients: evidence based on the variety of prescribing approaches among practicing Japanese rheumatologists in a single institute-based large observational cohort (IORRA). Mod Rheumatol. 2007;17: 98–105.
   PubMedGoogle Scholar
• Nakashima Y, Kondo M, Harada H, Horiuchi T, Ishinishi T, Jojima H, Kuroda K, Miyahara H, Nagamine R, Nakashima H, Otsuka T, Saikawa I, Shono E, Suematsu E, Tsuru T, Wada K, Iwamoto Y. Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate. Mod Rheumatol. 2010;343–52.
   Google Scholar
• Kishimoto T. Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res 'Ther. 2006;8[Suppl 2]:S2.
   Google Scholar
• Koike T, Harigai M, Inokuma S, et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheu-matol. 2009;36:898–906.
   PubMed Web of Science ®Google Scholar
• Kremer JM, Genant HK, Moreland LW, et al. Effects of abata-cept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006;144:865–76.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheu-matoid arthritis refractory to tumor necrosis factor alpha inhibi-tion. N Engl J Med. 2005;353:1114–23.
   PubMed Web of Science ®Google Scholar
• Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheuma-toid arthritis despite methotrexate treatment: results of a phase JIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006;54:1390–400.
   Google Scholar
• Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793–806.
   PubMed Web of Science ®Google Scholar
• Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modi-fying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58:2968–80.
   PubMed Web of Science ®Google Scholar
• Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves randomised placebo-controlled trial biologicals: results from a 24-week multicentre arthritis refractory to anti-tumour necrosis factor treatment outcomes in patients with rheumatoid. Ann Rheum Dis. 2008;67:1516–23.
   PubMed Web of Science ®Google Scholar
• Charles P, Elliott MJ, Davis D, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol. 1999;163:1521–8.
   PubMed Web of Science ®Google Scholar
• Butler DM, Maini RN, Feldmann M, et al. Modulation of pro-inflammatory cytokine release in rheumatoid synovial membrane cell cultures: comparison of monoclonal anti-TNF-alpha antibody with the IL-1 receptor antagonist. Eur Cytokine Netw. 1995;6: 225–30.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D, Koeller M, et al. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;370:1861–74.
   PubMed Web of Science ®Google Scholar
• Kishimoto T. The biology of interleukin-6. Blood. 1989;74:1–10.
   PubMed Web of Science ®Google Scholar
• Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors pre-dicting response to treatment in rheumatoid arthritis: the impor-tance of disease duration. Arthritis Rheum. 2000;43:22–9.
   PubMed Web of Science ®Google Scholar
• Nakamura I, Omata Y, Naito M, Ito K. Blockade of interleukin 6 signaling induces marked neutropenia in patients with rheumatoid arthritis. J Rheumatol. 2009;36:459–60.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Tatsuki Y, Nogami Y, et al. Postmarketing surveil-lance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67:189–94.
   PubMed Web of Science ®Google Scholar